TITLE

Multicentre trials: a US regulatory perspective

AUTHOR(S)
Anello, Charles; O'Neill, Robert T; Dubey, Satya
PUB. DATE
June 2005
SOURCE
Statistical Methods in Medical Research;Jun2005, Vol. 14 Issue 3, p303
SOURCE TYPE
Academic Journal
DOC. TYPE
journal article
ABSTRACT
Multicentre trials are very common in the field of drug development. In recent years, multicentre trials have taken on a multinational and multiregional aspect. We provide a conceptual framework for the use of multicentre trials in the context of drug development, from the perspective of drug regulation in the United States. In this paper, we review some regulatory history, milestones and standards as they relate to multicentre trials. Special attention is given to the similarities and differences in the approaches to multicentre trials in the following documents; Guideline for the Format and Content of the Clinical and Statistical Sections of New Drug Applications, International Conference on Harmonization, Draft Guideline on Statistical Principles for clinical trials and the Guidance for Industry Providing Clinical Evidence of Effectiveness for Human Drug and Biologic Products. The paper includes a consideration of some of the issues in the analysis of data from multicentre trials.
ACCESSION #
17109312

 

Related Articles

  • Antitumor Efficacy Testing in Rodents. Hollingshead, Melinda G. // JNCI: Journal of the National Cancer Institute;11/5/2008, Vol. 100 Issue 21, p100 

    The preclinical research and human clinical trials necessary for developing anticancer therapeutics are costly. One contributor to these costs is preclinical rodent efficacy studies, which, in addition to the costs associated with conducting them, often guide the selection of agents for clinical...

  • Reducing the number of failures in early stage development. Kermani, Faiz // Pharmaceutical Technology Europe;Jul2010, Vol. 22 Issue 7, p14 

    The article focuses on the importance of conducting the Phase 0 trial in the drug development in the U.S. and Europe. The phase 0 trial is being performed to reduce the number of drug failures and to reduce costs. The trial has been anticipated to determine the efficiency of the drug in humans...

  • Dermatology Clinical Trials and Drug Development. Ehrenberger, Heidi E.; Joshi, Teresa G. // Dermatology Nursing;Oct2003, Vol. 15 Issue 5, p428 

    Discusses the importance of understanding drug development and the implications for nursing practice. Modalities in dermatology that are coming in the market; Factors that are creating pressures and opportunities for stakeholders in the clinical trials arena; Function of the institutional...

  • New Drugs Are Spending More Time In Clinical Trials.  // RN;Feb2006, Vol. 69 Issue 2, p66 

    Reports on the increase in clinical trial time for new drugs, as observed by researchers at the Tufts Center for the Study of Drug Development in the U.S., as of 2005. Average time a new drug spends in clinical trials; Average number of years required for new medications to reach the market...

  • A strategic imperative for clinical trials in India. Bhatt, Arun // Australasian Biotechnology;Oct2010, Vol. 20 Issue 3, p28 

    The article recognizes the trends and developments that made India a popular option for clinical trials as regulatory processes improve. International pharmaceutical sponsors were skeptical to India's capability to host clinical trials during the late 1990s. But as of 2010, it participates in...

  • Phase III Failures: What Can Be Done? Beltangady, Mohan // Applied Clinical Trials;Sep2005, Vol. 14 Issue 9, p82 

    Looks at what can be done to prevent failures in Phase III clinical trials. Increasing costs of drug development; Possible reasons for why Phase III trials may fail to confirm what has been learned from Phase II studies; Value of flexible trial designs.

  • Medical Nanotechnology. Ferrari, Mauro; Downing, Gregory // BioDrugs;2005, Vol. 19 Issue 4, p203 

    Nanotechnology, the science of creating structures, devices, and systems with a length scale of approximately 1–100 nanometers, is poised to have a revolutionary effect on biomedical research and clinical science. By operating at the same scale as most biomacromolecules, nanoscale devices...

  • Impact on the Future. Doren, Philip E.; O'Donnell, Teri; Pearson, Jamie // Applied Clinical Trials;Jul/Aug2013, Vol. 22 Issue 7/8, p4 

    The article focuses on the application of Risk-based monitoring (RBM) for making drug development a more effective process while providing high quality results on time and under the budget. It mentions that RBM carefully analyzes the sources that impose meaningful threats to the goals of...

  • The Fine Art of Fine-Tuning Drug Formulation. Canavan, Neil // Drug Discovery & Development;Sep2005, Vol. 8 Issue 9, p26 

    Talks about the difficulties of drug development through clinical trials and the challenges emerge surrounding optimal drug formulation. Number of formulations that researchers have experimented; Administration of drugs; Determination of the responses of patients to various drug formulations. ...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics